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Osteoarthritis (OA) is one of the most prevalent joint diseases with prominent symptoms affecting the daily life of millions of 
middle aged and elderly people. Despite this, there are no successful medical interventions that can prevent the progressive de-
struction of OA joints. The onset of pathological changes in OA is associated with deviant activity of mesenchymal stem cells 
(MSCs), the multipotent precursors of connective tissue cells that reside in joints. Current therapies for OA have resulted in 
poor clinical outcomes without repairing the damaged cartilage. Intra-articular delivery of culture-expanded MSCs has opened 
new avenues of OA treatment. Pre-clinical and clinical trials demonstrated the feasibility, safety, and efficacy of MSC therapy. 
The Wnt/β-catenin, bone morphogenetic protein 2, Indian hedgehog, and Mitogen-activated protein kinase signaling pathways 
have been demonstrated to be involved in OA and the mechanism of action of MSC therapies. 
osteoarthritis, mesenchymal stem cells, intra-articular delivery 
 




Osteoarthritis (OA) is the most common form of arthritis, a 
disease that can affect all the structures of the joints [1]. It 
was estimated in 2007 that more than 100 million people in 
China suffered from OA [2]. In adults, OA is the second 
leading cause of work disability, and the costs of OA have 
grown exponentially to astronomical figures over recent 
decades, accounting for up to 1%–2.5% of the gross nation-
al product of countries with aging populations, including the 
USA, Canada, the UK, France, and Australia [3]. OA is not 
only a process of erosion, but also describes an anomalous 
remodeling of joint tissues resulting from obesity, joint in-
stability, or trauma [4]. The extensive pathologic changes in 
OA are identified as “joint failure”, which includes degra-
dation of the articular cartilage, osteosclerosis of the sub-
chondral bone, retrogression of cruciate ligaments, hyper-
plasia of the synovium, degeneration of menisci, and hyper-
trophy of the joint capsule [5]. Many treatments have been 
advocated, but most resulted in dissatisfactory clinical re-
sults without cartilage repair [6]. The only pharmacologic 
therapy for OA recommended by the American Academy of 
Orthopedic Surgeons (AAOS) is non-steroidal antiinflam- 
matory drugs (NSAIDs) or tramadol for patients with 
symptomatic osteoarthritis. Intra-articular injection of hya-
luronic acid is strongly not recommended [7]. In recent 
years, The New England Journal of Medicine published a 
series of results of controlled clinical trials showing little 
effect of arthroscopic surgery for the treatment of OA 
[8–11]. Furthermore, common treatments including physical 
therapy, viscosupplementation [12], glucosamine and/or 
chondroitin sulfate [13], and acupuncture [14] have demon-
strated modest to no clinical benefit when compared with 
placebo. Moreover, all these treatments are generally in-
tended to decrease pain, maintain or improve joint function, 
and minimize disability, not to regenerate joint tissue. 
Cell therapy by surgical autologous chondrocyte implan-
tation (ACI) has been used to regenerate chondral lesions 
for more than 20 years [15,16], and clinical trials have con-
firmed the efficacy of ACI. However, clinical trials with 
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contradictory outcomes have been published by different 
institutions when comparing ACI with other classical treat-
ments, particularly microfracture. Knutsen et al. assessed 80 
patients following either ACI or microfracture. At 24 
months, both groups showed significant clinical improve-
ment, and no significant differences were found between the 
methods in either histological quality of the regenerated 
tissue or clinical. However, microfracture was associated 
with better SF-36 physical component scores [17]. More 
recently, Saris et al. [18] evaluated the efficacy of micro-
fracture and characterized chondrocyte implantation (CCI) 
in 118 patients. At 12 and 18 months, CCI demonstrated 
better structural repair as measured by histological evaluation. 
At the 36 month follow-up, CCI showed a significant im-
provement not only in the overall Knee injury and Osteoar-
thritis Outcome Score (KOOS), but also in the subchondral 
bone reaction [19]. Nonetheless, at the 5 year follow-up, 
although the clinical benefit was retained, the overall KOOS 
was not different between the CCI and microfracture groups 
[20]. Furthermore, ACI has several inherent disadvantages, 
such as chondrocyte dedifferentiation during culture that 
might result in fibrocartilage rather than hyaline cartilage 
formation [21], the two-stage surgical procedure may cause 
further cartilage damage and degeneration [22], and chon-
drocyte yields and their in vitro proliferative capacity de-
crease with age, especially in older patients [23]. Most im-
portantly, ACI has been limited to focal cartilage defects 
caused by injury, while generalized cartilage loss in OA has 
been considered an exclusion criterion [15,16]. Recently, 
intra-articular injection of mesenchymal stem cells (MSCs) 
for the repair of joint surface lesions suggested the suitabil-
ity of MSCs to replace autologous chondrocytes as the cell 
source for OA cartilage repair [24–26]. The advantages of 
intra-articular injection of MSCs for the treatment of OA 
include the simplicity and ease of MSC delivery, minimum 
invasiveness, and avoiding the potential disease transmis-
sion caused by the xenograft coverage used in ACI. In this 
review, we summarize the characterization of MSCs, dif-
ferences between adipose-derived mesenchymal stem cells 
(A-MSCs) and bone marrow-derived mesenchymal stem 
cells (BM-MSCs), aberrant activity of MSCs in OA, pre-
clinical and clinical data of MSC therapies for OA, and po-
tential mechanisms of action, including the signaling path-
ways and tissue regeneration involved in the treatment of 
OA with MSCs. 
1  Mesenchymal stem cells and their phenotypes 
MSCs are precursors of connective tissue cells and were 
discovered by Alexander Friedenstein, who was the first to 
identify a group of fibroblast-like cells in the bone marrow 
of mice and guinea pigs with the capacity not only to dif-
ferentiate into osteocytes, but also to form colonies from a 
single cell, referring to them as colony-forming units fibro-
blastic (CFU-F) [27,28]. In 1991, Arnold Caplan suggested 
naming these cells ‘mesenchymal stem cells’ because they 
were capable of differentiation into all the cells of meso-
dermal lineage [29]. The minimum criteria for MSCs in-
clude plastic adherence and in vitro tri-lineage differentia-
tion to adipogenic, chondrogenic, and osteogenic cells [30]. 
Additional requirements include cell surface expression of 
CD105, CD73, and CD90 and the absence of the hemato-
poietic markers CD45, CD19, CD79, CD11b, and HLA-DR. 
Nevertheless, the absence of a single specific marker that 
defines MSCs remains a particular challenge. Recently, a 
key potential marker for MSC enrichment, CD271 or 
low-affinity nerve growth factor receptor (LNGFR), was 
discovered [31]. After purification, CD271+ non-hemato- 
poietic bone marrow cells appear to contain all the colony 
forming cells [32], and CD271+ cells demonstrate tri-   
lineage differentiation potential [31]. An additional marker, 
CD146 or melanoma cell adhesion molecule (MCAM), was 
also reported [32]. In human bone marrow, CD146 is ex-
pressed by a subpopulation of CD271bright cells, and the 
main subgroup in adults is CD271bright/CD146− cells, while 
the CD271bright/CD146+ subgroup is dominant in pediatric 
and fetal bone marrow [33]. Both CD271+/CD146+ and 
CD271+/CD146− cell fractions express classical MSC 
markers, including CD73, CD90, and CD105, and have 
tri-lineage differentiation potential. Furthermore, CD146 
expression in vivo is localized to the perivascular regions 
within CD271-expression cells, while endosteal CD271 
expressing cells lacked CD146 expression [32]. 
In addition to bone marrow, MSC populations can be 
isolated from dental pulp [34], umbilical cord blood [35], 
synovial membrane [36], adipose tissue [37], placenta [38], 
skin [39], umbilical cord perivascular cells [40], skeletal 
muscle [41], Wharton’s jelly [42], meniscus [43], breast 
milk [44], cartilage [45], ligament [46], and fat pad [47]. 
The different sources of MSCs and their different pheno-
typic properties are shown in Table 1. 
2  Differences between adipose- and bone mar-
row-derived MSCs 
Adipose tissue is both an energy reservoir and a complex 
endocrine organ containing adipose-derived mesenchymal 
stem cells (A-MSCs). A-MSCs were first described as adi-
pocyte precursors by Frohlich in 1972 [48]. Further investi-
gations demonstrated the stem cell-like plasticity of 
A-MSCs and their capacity to differentiate into cells of 
mesodermal origin, such as adipocyte, osteocyte, chondro-
cyte, and myocyte lineages [49]. A-MSCs are now consid-
ered an attractive source of MSCs because of the large 
numbers of cells that can be harvested with relatively little 
donor morbidity. Compared with BM-MSCs, A-MSCs are 
more easily cultured and grow more rapidly [50]. The main 
benefits of A-MSCs are that their proliferation and differen-
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Table 1  Characterization and phenotypic properties of MSCs from different sources 
Cells source Character identification Phenotype Reference 
Umbilical 
cord blood 
Positive: CD13, CD29, CD49e, CD54, CD90 a-smooth muscle actin 
Negative: CD14, CD31, CD34, CD45, CD49d CD106 
Rich in mesenchymal progenitors, similar to 
haematopoietic progenitors. 
Erices et al.  
(2000) [35] 
Dental pulp 
Positive: CD44, CD29, CD106, a-smooth muscle actin 
Negative: CD14, CD34, CD45 
Produces only sporadic, but densely calci-
fied, nodules, and does not form adipocytes. 




Positive: CD44, CD73, CD90, CD105, CD166, CD271 
Stable, proliferative population with higher 
chondrogenic potential. 




Positive: CD73, CD90, CD105 
Negative: CD31, CD34, CD45 
Higher potential yields of MSCs with chon-
drogenic, adipogenic, ostseogenic, and myo-
genic potential. 
Zuk et al.  
(2001) [37] 
Placenta 
Positive: CD90, CD105, CD166, CD49e, SH3, SH4,  HLA-ABC 
Negative: CD31, CD34, CD45, CD49d, CD123, HLA-DR 
Higher expansion potency compared to bone 
marrow-derived MSCs. 






Positive: CD105, CD73, CD90, CD44 
Negative: CD45, CD34, CD235a, CD106, CD123, SSEA-4, 
HLA-DR, DP, DQ (MHC II), HLA-G, Oct4 
Normal, rapidly expandable, MHC–/– cells 
containing a subpopulation that exhibits a 
functional osteogenic phenotype and elabo-
rated bone nodules. 
Sarugaser et al.  
(2005) [40] 
Skin 
Positive: CD90, SH2, SH4, HLA I, CD44, CD49d, CD49e, CD49f, 
CD166, CD105, EGFR, PDGFR 
Negative: CD45, CD38, CD34, CD31 
Effectively differentiate into neuronal pre-
cursors better than bone marrow-derived 
MSCs. 




Positive: NG2, CD146 
Negative: CD144, CD34, CD31 
Strong myogenicity potential with typical 
MSC surface marker patterns. 




Positive: CD10, CD13, CD29, CD44, CD90, CD105 
Negative: CD34, CD45, CD14, CD33, CD56, CD31, HLA-DR 
Greater expansion capability, faster growth in 
vitro, and different cytokine secretome com-
pared to bone marrow MSCs. 
Troyer et al.  
(2008) [42] 
Meniscus 
Positive: CD90, CD105, CD166, CD44 
Negative: CD34, CD45 
Less activity compared to synovium or bone 
marrow MSCs. 
Segawa et al.  
(2009) [43] 
Cartilage Positive: CD49e, Notch1, CD90, STRO‑1 Higher fibronectin affinity and stronger col-
ony- forming efficiency. 
Williams et al.  
(2010) [45] 
Breast milk 
Positive: CD44, CD29, SCA-1, SMA, vimentin, nestin 
Negative: r CD33, CD34, CD45, CD73 
Normally proliferative, with chondrogenic, 
osteogenic and adipogenic activity and nor-
mal MSCs phenotypes. 
Patki et al.  
(2010) [44] 
Ligament 
Positive: CD29, CD44, CD49c, CD73, CD90, CD97, CD105, 
CD146, and CD166 
Weekly positive: CD106, CD14 
Negative: CD11c, CD31, CD34, CD40, CD45, CD53, CD74, 
CD133, CD144, CD163 
Lower ability in chondrogenesis, osteogene-
sis and adipogenesis compared with bone 
marrow MSCs. 
Higher activity in ligamentogenesis. 
Steinert et al.  
(2011) [46] 
Fat pad 
Positive: CD13, CD44, CD90, CD105, CD29 
Negative: CD271, STRO1, CD34, CD56 
Highly proliferative, strong chondrogenic, 
osteogenic and adipogenic activities. 
Khan et al.  
(2012) [47] 
 
tiation potentials and telomerase are less affected by age 
than those of BM-MSCs [51]. 
A-MSCs and BM-MSCs have slightly different cell sur-
face marker profiles. Most recently, characterization of ca-
nine A-MSCs and BM-MSCs identified that canine 
A-MSCs and BM-MSCs both demonstrated strong expres-
sion of CD29 and CD44, moderate expression of CD90, and 
were negative for CD34 and CD45. Oct3/4 and Sox2 were 
equally expressed in canine A-MSCs and BM-MSCs, while 
Nanog expression was 2.5-fold higher in A-MSCs than in 
BM-MSCs [52]. Markers of human A-MSCs include 
STRO-1, CD146, and 3G5, in which the 3G5-positive frac-
tion demonstrated the greatest enrichment for CFU-F com-
pared with the other sorted cell populations [53]. However, 
there are slight differences in the cell surface phenotype 
profiles between A-MSCs and BM-MSCs despite sharing 
expression of key markers CD9, CD10, CD29, CD44, CD90, 
CD105, CD117, CD146, and STRO-1 [54]. Human 
A-MSCs express CD49d (VLA-4), which is not expressed 
by BM-MSCs, while A-MSCs lacked the expression of 
CD106 (VCAM-1), which was expressed by BM-MSCs 
[54]. This reciprocal expression is quite interesting because 
CD106 is the cognate receptor of CD49d. Moreover, only a 
small fraction of ex vivo expanded human BM-MSCs ex-
press STRO-1, while most human A-MSCs express it [55]. 
The differentiation potentials of A-MSCs and BM-MSCs 
are also slightly different. Compared with BM-MSCs, A- 
MSCs have lower innate chondrogenesis, though high-dose 
combinations of growth factors (TGFβ2 and IGF-1) were 
capable of inducing comparable chondrogenesis in both cell 
types [56]. Recently, the impact of culture medium on the 
differentiation capacity of A-MSCs and BM-MSCs has 
been investigated. Human serum derivatives (throm-
bin-activated platelet-rich plasma or human platelet lysates) 
can lead to spontaneous osteogenesis in BM-MSCs and 
strong adipogenesis in A-MSCs expanded in vitro compared 
with fetal bovine serum-supplemented media [57,58]. 
The immunomodulative ability of MSCs is considered to 
be one of their most important properties. In response to 
inflammatory molecules such as interleukin-1 (IL-1), tumor 
necrosis factor-alpha (TNF-α), and interferon-gamma 
(INF-γ), MSCs secrete a variety of growth factors and an-
ti-inflammatory cytokines that feed back to many types of 
immune cell [59,60]. A-MSCs, like BM-MSCs, are negative 
for MHC class II molecules, CD80-B7, and CD40 [6163]. 
By contrast, A-MSCs prohibit B cell proliferation, decrease 
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immunoglobulin production, and restrict B cell functions 
more significantly than BM-MSCs [64]. 
3  Atypical activity of MSCs in OA 
Although various investigations have demonstrated an 
atypical or defective activity of MSCs during OA progres-
sion, the relationship between this atypical activity of MSCs 
and OA progression itself remains unknown. Murphy et al. 
[65] revealed that bone marrow MSCs isolated from 
end-stage OA patients exhibit deficient proliferation and 
differentiation potentials compared with BM-MSCs from 
healthy, age-matched controls. In addition to a diminished 
yield and proliferative activity in OA MSCs, they also show 
a modified differentiation profile with decreased chondro-
genesis and adipogenesis and increased osteogenesis. These 
aberrant activities in OA MSCs can be rescued by supple-
mentation of the culture medium with growth factors such 
as epidermal growth factor or fibroblast growth factor 2 
[66,67]. Human periosteal MSCs from donors younger than 
30 years show spontaneous chondrogenesis in culture, while 
older donors do not exhibit spontaneous chondrogenesis 
[68]. Trabecular bone MSCs sorted on the basis of CD271 
expression revealed that OA MSCs exhibit an age-related 
proliferation deficiency in vitro [69]. In OA patients, the 
number of MSCs in the synovial fluid compartment is much 
greater than in samples from healthy joints, and the number 
of cells increased with the severity of OA progression [70]. 
Synovial fluid MSCs show greater chondrogenic capability 
than MSCs separated from bone marrow [71]. 
4  MSC therapy for OA 
Murphy et al. [24] were the first to propose the direct, intra- 
articular delivery of MSCs for the treatment of OA in a goat 
model. OA was induced by medial meniscectomy and ante-
rior cruciate ligament transection (ACLT) for six weeks, 
and 10 million autologous BM-MSCs with sodium hyalu-
ronan were injected. Twenty weeks after injection, the de-
generation of articular cartilage, osteophyte formation, and 
subchondral bone thickening were reduced in the cell- 
treated joints. 
Since then, a great deal of attention has been focused on 
the intra-articular injection of expanded BM-MSCs on ani-
mal models of OA (Table 2). In a porcine cartilage defect 
model, seven million autologous BM-MSCs were injected 
into 8 mm long and 1 mm deep defects, and 6–12 weeks 
later, the cell-treated groups exhibited improved cartilage 
healing both histologically and morphologically, expressing 
the hyaline cartilage marker type II collagen [72]. In a rab-
bit model, OA was induced by ACLT for eight weeks and 
two million autologous BM-MSCs with a hyaluronan-based 
scaffold were delivered to the joint by intra-articular injec-
tion. Three to six months after surgery, the cartilage ap-
peared significantly regenerative, expressing more type II 
collagen compared with the scaffold alone group. In addi-
tion, the cartilage matrix-degrading enzymes matrix metal-
loproteinase 1 and 3 (MMP-1, MMP-3) were decreased in 
the cell-treated group [73]. To track the injected MSCs, 
transgenic rats expressing dual luciferase (Luc) and LacZ 
were used in a rat massive meniscal defect model [74]. 
Twelve weeks after five million allogeneic Luc/LacZ+ syn-
ovium-MSCs were injected, LacZ-positive regenerated me-
nisci producing type II collagen were found, and the LacZ 
gene derived from MSCs was not found in any other organs 
except in synovium. In a spontaneous OA model in guinea 
pigs, seven million human commercial MSCs (Lonza, Basel, 
Switzerland) with hyaluronic acid (HA) were injected into 
the OA joint [75]. Five weeks after transplantation, partial 
cartilage regeneration with type II collagen expression was 




Cell source Scaffold Dose/cells Outcome Reference 
ACLT+ meniscec-





Degeneration of the articular cartilage, osteophytic 
remodeling, and subchondral sclerosis were reduced in 
cell-treated joints. 
Murphy et al.  
(2003) [24] 
Partial-thickness 






At 12 weeks, the Wakitani scores showed marked 
improvement in the quality of the repair tissue seen in 
the MSC treated group. 









The histological score of the treated group was con-
sistently better at 4, 12, and 24 weeks than controls. 
The MSC suspension promoted cartilage regeneration. 
Koga et al.  









Defects were filled with hyaline cartilage-like tissue 
with zonal organization and intense glycosaminoglycan 
staining. 
Guo et al.  
(2010) [100] 





human MSC  
HA 7×106 
At 5 weeks post transplantation, partial cartilage repair 
was noted in the HA-MSC group with type II collagen 
around both residual chondrocytes and transplanted 
MSCs in the OA cartilage. 
Sato et al.  
(2012) [75] 




Treatment reduced matrix degrading enzymes and 
TNF-α in the cartilage matrix and inhibited MMP-1 
and TNF-α expression in the synovial membrane and 
menisci. 
Giovanna et al.  
(2013) [97]  
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noted in the cell-treated group. 
These successful preclinical studies led to the initiation 
of many clinical trials (Table 3). The majority of these re-
ports involved the use of autologous, culture-expanded 
BM-MSCs or A-MSCs. Notably, the majority of technical 
approaches used intra-articular injection to deliver the 
MSCs to the synovial fluid compartment using a hyaluronan 
scaffold, which is a major component of synovial fluid. The 
clinical reports listed in Table 3 tested cell injection doses 
from one to one hundred million cells in a single injection. 
In a prospective, randomized, controlled clinical trial 
with two years follow-up, the microfracture with autologous 
BM-MSCs treatment group (28 patients) achieved signifi-
cant improvements in the Tegner Lysholm and International 
Knee Documentation Committee (IKDC) scores. Magnetic 
resonance imaging (MRI) scans performed one year after 
the surgical intervention showed significantly better Mag-
netic Resonance Observation of Cartilage Repair Tissue 
(MOCART) scores for the cell-recipient group than the mi-
crofracture alone group (28 patients) [76]. In a pilot study of 
12 OA patients with intra-articular injection of 40 million 
autologous expanded BM-MSCs, the patients showed a 
large improvement in algofunctional indices by one year, 
and MRI scanning exhibited a 27% decrease in poor carti-
lage areas with improvement of cartilage quality in 11 of the 
12 patients [77]. Most recently, two clinical trials have at-
tracted a lot of interest. In an Osiris Therapeutics Inc. fund-
ed, randomized, double-blinded, controlled clinical trial 
[25], 55 patients at seven institutions experienced a partial 
medial meniscectomy followed by injection with (5–   
15)×107 allogeneic BM-MSCs and/or sodium hyaluronate as 
a vehicle control. At the two year follow-up, the meniscal 
volume achieved a 15% threshold in 24% of patients deter-
mined by quantitative MRI, indicating evidence of meniscus 
regeneration after treatment with allogeneic human BM- 
MSCs. Another intriguing proof-of-concept clinical trial in 
which patients with OA were treated with (1–10)×107 au-
tologous A-MSCs also demonstrated improved Western 
Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) scores at six months after injection in the 
10×107 dose group [26]. Most importantly, the arthroscopy 
and histological assessments showed substantial thick, hya-
line-like cartilage regeneration, suggesting that the in-
tra-articular injection of A-MSCs regenerated hyaline-like 
articular cartilage without causing adverse events. All of 
these pre-clinical investigations and clinical trials demon-
strated that the intra-articular injection of MSCs into an OA 
joint was not associated with apparent adverse events, but 
instead showed improved function, reduced pain, and re-
generated hyaline-like cartilage in the affected joint.
Table 3  Clinical trials of MSC treatment for OA 
Indications Cell source Dose/cells Study design Outcome Reference 






24 weeks follow-up visit after intra-articular 
injection 
The patient had statistically significant carti-
lage and meniscus growth by MRI, as well as 
increased range of motion and decreased 
modified VAS pain scores. 
Centeno 
et al. (2008)  
[101]  
50 patients  






Received MSC concentrate injection along 
with the arthroscopic debridement 
The overall osteoarthritis outcome score, 
especially the quality of life, was improved. 
Varma et al.  
(2010) [102] 
4 patients  
with moderate 




(8–9)×106 Intra-articular injection of cultured MSCs 
The walking time and pain improved for 3 
patients, and 1 patient remained unchanged. 
Davatchi 
et al. (2011)  
[103] 
12 patients  





Intra-articular injection of cultured MSCs with 
PRP 
The mean Lysholm score, Tegner activity 
scale, and VAS scores of patients in the 
study group improved significantly. 
Koh et al. 
(2012) [104] 







Intra-articular injection of cultured MSCs with 
hyaluronic acid 3 weeks after HTO and mi-
crofracture 
The treatment was effective in improving 
both short-term clinical and MOCART out-
comes. 
Wong et al. 
(2013) [76] 
12 patients  





1 year follow-up visit after intra-articular 
injection 
Patients exhibited rapid and progressive 
improvement of algofunctional indices that 
approached 65% to 78% after 1 year. 
Orozco et al. 
(2013) [77] 
18 patients  




The phase I study consisted of intra-articular 
injection of 3 dose-escalation cohorts. The 
phase II study included 9 patients receiving 
the high-dose and their 6 months follow-up 
visit 
Intra-articular injection of the high dose 
improved function and pain of the knee joint 
without causing adverse events, and reduced 
cartilage defects by regeneration of hya-
line-like articular cartilage. 
Jo et al.  
(2014) [26] 
55 patients  






A single superolateral knee injection of cul-
tured MSCs 7 to 10 days after the meniscec-
tomy 
Treated patients had a significant reduction 
in pain, along with significantly increased 
meniscal volume. 
Vangsness 
et al. (2014) 
[25]  
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5  Potential mechanisms involved in OA pro-
gression and MSC treatment 
In OA joints, the synovium appears to have at least two cru-
cial roles in the development and progression of OA. On 
one hand, synovium might be the target of effective repair 
responses involving endogenous MSCs. On the other hand, 
the resident cell population within the synovium affects the 
homeostasis of the joint, and can initiate degenerative 
changes in OA [78,79]. The infiltration of CD4+ T cells and 
CD68+ macrophages is essentially increased in the synovi-
um during early-stage compared with late-stage OA [80]. 
Moreover, cytokines, including interleukin-1 beta (IL-1β) 
and TNF-α, and chemokines (CCL 19 and monocyte chem-
otactic protein 1) may be released from the synovium, stim-
ulating articular chondrocytes by activating various cell 
surface receptors, including Toll-like receptors (TLRs), and 
thereby promoting cartilage catabolism and inhibiting ma-
trix synthesis [81]. All these data suggest that synovial in-
flammation is a feature in the early-stages of OA and might 
initiate the degenerative cascades that result in tissue de-
struction. 
Chondrocytes also play an important role in OA progres-
sion via several signaling pathways. Chondrocytes can   
be activated through the nuclear factor kappa B (NF-    
B), stress-induced, and mitogen-activated protein kinase 
(MAPK) pathways by mechanical and inflammatory stimuli 
to express cytokine and chemokine receptors, MMPs, cy-
clooxygenase 2 (COX-2), and IL-1 [82]. Cartilage ma-
trix-degrading enzymes secreted by chondrocytes and syno-
vial cells include aggrecanases and collagenases. Matrix 
degradation during early-stage OA may be caused by ag-
grecanases, MMP-3, and a disintegrin and metalloproteinase 
with thrombospondin motifs 5 (ADAMTS-5) activities, 
followed by increased activity of collagenase MMP-13, 
which is highly efficient at degrading type II collagen [83]. 
These results were confirmed in global knockout 
Adamts-5−/− mice, which exhibited protection against OA 
progression and in global knockout Mmp-13−/− mice, which 
showed inhibition of cartilage erosion [84,85]. Recently, the 
canonical Wnt/β-catenin signaling pathway was suggested 
to have dual effects on cartilage destruction during OA pro-
gression. A global knockout Frzb−/−, a Wnt antagonist, ex-
hibited greater cartilage loss than wild type controls, and the 
increased cartilage damage was associated with increased 
levels of β-catenin-dependent Wnt signaling and matrix 
metalloproteinase 3 [86]. Another experiment also found 
that Wnt antagonist Dkk-1 chondrocyte-specific transgenic 
mice, Col2α1-Dkk1, had significantly mitigated surgery- 
induced OA because of decreased Mmp13 and Adamts4 
expression compared with their wild-type littermates, while 
Wnt-3a, an agonist of Wnt, induced Mmp13 and Adamts4 
expression in chondrocytes in primary culture [87]. Howev-
er, further investigation found that Wnt-3a could block 
IL-1β-induced MMP-1 and MMP-13 expression, while 
co-incubation with Dkk-1 increased IL-1β-induced expres-
sion of MMPs. This indicates a negative feedback loop 
wherein Wnt/β-catenin signaling in human chondrocytes 
played an anti-catabolic role by preventing MMP expres-
sion induced by IL-1β [88]. Another investigation also 
found that SOST, a potent inhibitor of canonic Wnt signal-
ing that binds to Wnt receptor Low-density-lipoprotein re-
ceptor-related protein 5/6 (LRP5/6), inhibited further deg-
radation of OA cartilage [89]. More recently, bone mor-
phogenetic protein 2 (BMP-2) signaling was found to in-
crease β-catenin nuclear translocation, LRP-5 expression, 
MMP levels (MMP-9, MMP-13, and MMP 14), ADAMTS- 
5, and collagen X expression. The BMP-2-induced LRP-5 
up-regulation was mediated by Smad1/5/8 binding on the 
LRP-5 promoter, which contributed to the hypertrophy of 
OA chondrocytes via crosstalk with canonical Wnt/β- 
catenin signaling [90]. 
Whether subchondral bone thickening precedes fibrilla-
tion of the cartilage or not remains controversial. Recently, 
articular chondrocytes isolated from normal joints were 
found to prohibit normal subchondral bone osteoblastogen-
esis, whereas chondrocytes isolated from OA joints streng- 
thened subchondral bone osteoblastogenesis by significantly 
activating ERK 1/2 phosphorylation in co-culture, indicat-
ing that OA chondrocytes may alter subchondral bone os-
teoblastogenesis via the MAPK signaling pathways [91]. 
Interestingly, OA subchondral bone osteoblasts were also 
able to increase articular chondrocyte differentiation by 
inhibiting p38 phosphorylation and inducing ERK 1/2 
phosphorylation [92]. 
In terms of the mechanism of action of MSC therapy for 
OA, a recent investigation found that injection of human 
MSCs promoted rat meniscal regeneration by expressing rat 
collagen II, whereas a hedgehog antagonist prohibited, and 
a hedgehog agonist promoted rat collagen II expression. 
These data suggest that intra-articular injection of hMSCs 
repaired cartilage by activating the Indian hedgehog signal-
ing pathway [93]. The expression of Notch-1 was also 
found in MSCs from healthy and OA articular cartilage, but 
the numbers of Notch-1-positive MSCs were much larger 
when isolated from OA articular cartilage than healthy 
samples [94], indicating that Notch signaling is overex-
pressed during OA progression and that intra-articular ther-
apy with normal MSCs down-regulates the Notch signaling 
pathway. The transient receptor potential vanilloid 4 (TRPV 
4) ion channel, a Ca2+-preferred cation channel, was also 
found to play an important role in the progression of OA in 
mice using a global Trpv4 knock out [95]. Further investi-
gations have demonstrated that BM-MSCs from Trpv4−/− 
mice showed decreased adipogenesis and osteogenesis 
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phenotypes, whereas A-MSCs from Trpv4−/− mice exhibited 
increased adipogenesis and osteogenesis and decreased 
chondrogenesis compared with those in wild type controls, 
indicating that Trpv4 plays a chondroprotective role during 
OA progression [96]. Recent investigations found that in 
OA animal models, intra-articular injection of MSCs de-
creased articular cartilage erosion, probably by inhibiting 
MMP-13, TNF-α, and IL-1β expression [75,97]. Because 
MMP-13, TNF-α, and IL-1β expressions were associated 
with Wnt/β-catenin, MAPK, and BMP signaling based on 
the studies mentioned above, we inferred that these signals 
may also be involved in the effects of MSC treatment on 
OA (Figure 1). 
6  Conclusion 
In conclusion, OA is a disease characterized by progressive 
and irreversible destruction of the entire joint structure. OA 
seems to occur because of changes in the quantity, pheno-
type, and differentiation potential of resident mesenchymal 
cells. Nevertheless, current therapies, including conserva-
tive treatments and surgery, result in poor clinical outcomes 
with no cartilage repair. Successful pre-clinical results using 
intra-articular injection of MSCs provide the impetus for 
considering injection of MSCs as a useful therapy for this 
obstinate disease. Recent clinical studies have demonstrated 
exciting results with hyaline-like cartilage regeneration ac-
companied by pain relief, joint function improvement, and 
amelioration of the joint’s health condition. Several signal-
ing pathways have been found to be altered, along with 
changes in the functions, of joint-resident MSCs during OA 
progression, suggesting the necessity of exogenous MSC 
transplantation. 
However, there are still a large number of unanswered 
questions, some of which are exigent. For example, does 
MSC treatment repair the cartilage degradation, synovitis, 
and subchondral bone sclerosis directly or through paracrine 
effects? Which factors released by MSCs protect cartilage 
from degradation or trigger regeneration or repair of carti-
lage? What are the mechanisms of the cross-talk and feed-
back between injected MSCs and synovium, articular carti-
lage, and subchondral bone, and which are relevant to di-
recting disease progression and remission? Answering these 
questions will most likely require systemic approaches that 
apply molecular level genomics, epigenetics, proteomics, 
and metabolomics to investigate the mechanisms of action 
of MSCs during OA treatment. 
 
 
Figure 1  Potential mechanisms involved in OA progression and MSC treatment. Intra-articular injection of hMSCs promotes rat meniscal regeneration by 
expression of rat collagen II via Indian Hedgehog (IHH) signaling, whereas Smoothened IHH antagonist cyclopamine prohibited, and Smoothened IHH 
agonist SAG promoted, rat collagen II expression. BMP-2 signaling may not only increase MMP levels directly, but also increase β-catenin translocation via 
crosstalk with canonical Wnt/β-catenin signaling. Wnt-3a, an agonist of Wnt, may induce MMP13 and ADAMTS-4 expression, while Frzb−/− mice exhibited 
cartilage loss and Dkk1 transgenics showed cartilage gain, though both were Wnt antagonists. MAPK signaling may also activate chondrocytes to secrete 
ADAMTS and MMPs. 
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